Viatris (VTRS) Change in Receivables (2020 - 2026)
Viatris (VTRS) posted Change in Receivables of $126.5 million for Q2 2026, little changed on a QoQ basis from $126.3 million in Q1 2026, and up 1217.71% year-over-year from $9.6 million in Q2 2025.
Analysis
Viatris (VTRS) Change in Receivables (2020 - 2026) Analysis & Trends
Viatris has reported Change in Receivables for 7 years, with the latest figure at $126.5 million in Q2 2026.
- On a quarterly basis, Change in Receivables rose 1217.71% year-over-year to $126.5 million in Q2 2026; TTM through Jun 2026 was $76.6 million, a 117.99% increase from a year earlier, with the FY2025 full-year figure at -$334.6 million, down 11.5% from the prior year.
- Change in Receivables was $126.5 million for Q2 2026 at Viatris, roughly flat from $126.3 million in the prior quarter.
- The five-year high for Change in Receivables was $339.2 million in Q4 2022, with the low at -$300.5 million in Q4 2024.
- Average Change in Receivables over 5 years is -$12.2 million, with a median of $18.2 million recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables soared 3361.22% in 2022, then plunged 1614.29% in 2025.
- Over 5 years, Change in Receivables stood at $339.2 million in 2022, then tumbled by 124.0% to -$81.4 million in 2023, then sank by 269.16% to -$300.5 million in 2024, then rose by 9.52% to -$271.9 million in 2025, then surged by 146.52% to $126.5 million in 2026.
- The last three Change in Receivables figures came in at $126.5 million (Q2 2026), $126.3 million (Q1 2026), and -$271.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.55 Bn | 38.89 Bn | 2.15 Bn | 91.00 Mn |
| 2 | Viatris | 19.15 Bn | 18.26 Bn | 1.46 Bn | 126.50 Mn |
| 3 | Dr Reddys Laboratories | 9.87 Bn | 9.70 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.32 Bn | 334.51 Mn | 169.78 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 70.00 Mn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | 1.24 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 19.08 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | -2.98 Mn |
| 9 | Fennec Pharmaceuticals | 401.76 Mn | 360.51 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 126.50 Mn |
| Mar 31, 2026 | 126.30 Mn |
| Dec 31, 2025 | -271.90 Mn |
| Sep 30, 2025 | 95.70 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | -168.00 Mn |
| Dec 31, 2024 | -300.50 Mn |
| Sep 30, 2024 | 33.00 Mn |
| Jun 30, 2024 | -22.80 Mn |
| Mar 31, 2024 | -9.80 Mn |
| Dec 31, 2023 | -81.40 Mn |
| Sep 30, 2023 | 72.00 Mn |
| Jun 30, 2023 | 145.80 Mn |
| Mar 31, 2023 | -215.00 Mn |
| Dec 31, 2022 | 339.20 Mn |
| Sep 30, 2022 | -241.20 Mn |
| Jun 30, 2022 | 26.80 Mn |
| Mar 31, 2022 | 115.50 Mn |
| Dec 31, 2021 | 9.80 Mn |
| Sep 30, 2021 | -183.80 Mn |